The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Health Equity
Stay updated with the latest insights and developments in cancer care.
Antibody Drug Conjugates
By Editorial Team
_**Author**: **Dr. Arya Mariam** **Roy** from Roswell Park Comprehensive Cancer Center_ **What are antibody drug conjugates (ADCs)?** Antibody drug conjugates (ADCs) are newer targeted medicines...
Antibody Drug Conjugates
By Editorial Team
_**Author**: **Dr. Arya Mariam** **Roy** from Roswell Park Comprehensive Cancer Center_ **What are antibody drug conjugates (ADCs)?** Antibody drug conjugates (ADCs) are newer targeted medicines...
Antibody Drug Conjugates
By Editorial Team
_**Author**: **Dr. Arya Mariam** **Roy** from Roswell Park Comprehensive Cancer Center_ **What are antibody drug conjugates (ADCs)?** Antibody drug conjugates (ADCs) are newer targeted medicines...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
2022 Updates in Lung Cancer Treatment
By Editorial Team
By Dr. Kanak Parmar [Texas Tech University](https://www.ttu.edu/) ### **Perioperative systemic therapy for resectable non-small cell lung cancer** Surgical resection followed by adjuvant chemothe...
2022 Updates in Lung Cancer Treatment
By Editorial Team
By Dr. Kanak Parmar [Texas Tech University](https://www.ttu.edu/) ### **Perioperative systemic therapy for resectable non-small cell lung cancer** Surgical resection followed by adjuvant chemothe...
2022 Updates in Lung Cancer Treatment
By Editorial Team
By Dr. Kanak Parmar [Texas Tech University](https://www.ttu.edu/) ### **Perioperative systemic therapy for resectable non-small cell lung cancer** Surgical resection followed by adjuvant chemothe...
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Binaytara Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Binaytara Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Binaytara Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
Announcing Binaytara's 2023 Summit on Cancer Health Disparities (SCHD23)
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Announcing Binaytara's 2023 Summit on Cancer Health Disparities (SCHD23)
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Announcing Binaytara's 2023 Summit on Cancer Health Disparities (SCHD23)
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Binaytara Foundation Announces Dr. Umang Swami as Editor-in-Chief of the International Journal of Cancer Care & Delivery (IJCCD)
By Editorial Team
Swami Envisions the IJCCD as a Leading Journal in Cancer Health Disparities --------------------------------------------------------------------------- The Binaytara Foundation has named Dr. Umang Sw...
Binaytara Foundation Announces Dr. Umang Swami as Editor-in-Chief of the International Journal of Cancer Care & Delivery (IJCCD)
By Editorial Team
Swami Envisions the IJCCD as a Leading Journal in Cancer Health Disparities --------------------------------------------------------------------------- The Binaytara Foundation has named Dr. Umang Sw...
Binaytara Foundation Announces Dr. Umang Swami as Editor-in-Chief of the International Journal of Cancer Care & Delivery (IJCCD)
By Editorial Team
Swami Envisions the IJCCD as a Leading Journal in Cancer Health Disparities --------------------------------------------------------------------------- The Binaytara Foundation has named Dr. Umang Sw...